Bruton's Tyrosine Kinase (BTK) Inhibitors
Bruton's tyrosine kinase (BTK), also known as agammaglobulinemia tyrosine kinase (ATK) or B-cell progenitor kinase (BPK), is a non-receptor tyrosine kinase that was initially identified as the defective protein in human X-linked agammaglobulinemia (XLA). BTK is a member of the Tec family of protein tyrosine kinases and plays a major role in B-lymphocyte development, differentiation, and signaling. Mutations in the Btk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice. Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-kappaB (NF-kB) and nuclear factor of activated T cells (NFAT). Inhibition of BTK will be of therapeutic significance in the treatment of both B cell-related hematological cancers (e.g. non-Hodgkin lymphoma (NHL) and B cell chronic lymphocytic leukemia (B-CLL), and autoimmune diseases (e.g. rheumatoid arthritis). BioVision is pleased to offer a number of small molecule BTK inhibitors for research.
